Video Experimental Relacionado
Updated: Jun 25, 2025

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
250
Unirse a un ensayo de cáncer no mejora las probabilidades de supervivencia
Resumen
Un nuevo estudio desafía las ventajas comúnmente asumidas para los participantes en la investigación. Este hallazgo puede afectar el reclutamiento de ensayos clínicos futuros y las consideraciones éticas.
Área de la Ciencia:
- Investigación clínica
- Bienestar de los participantes
Sus antecedentes:
- Los ensayos clínicos a menudo asumen beneficios directos para los participantes.
- El alcance de estos beneficios es a menudo implícito en lugar de demostrado explícitamente.
Objetivo del estudio:
- Evaluar críticamente los beneficios a menudo implícitos de la participación en estudios clínicos.
- Proporcionar información basada en la evidencia sobre las ventajas para los participantes.
Principales métodos:
- Revisión sistemática de la literatura existente.
- Metaanálisis de los resultados informados por los participantes.
- Análisis cualitativo de las experiencias reportadas por los participantes.
Principales resultados:
- La evidencia de beneficios directos y tangibles fue menos consistente de lo comúnmente asumido.
- Algunos estudios mostraron una ventaja mínima o nula para los participantes.
- Variabilidad de los beneficios comunicados en diferentes tipos y condiciones de estudio.
Conclusiones:
- Los supuestos beneficios para los participantes en ensayos clínicos merecen un examen más minucioso.
- La investigación futura debe centrarse en cuantificar y verificar las ventajas para los participantes.
- Las directrices éticas pueden necesitar revisión para reflejar los resultados reales de los participantes.
Videos de Conceptos Relacionados
Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Hazard Ratio
111
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
111
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Actuarial Approach
74
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
74
Kaplan-Meier Approach
129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129

